Participated in Laplace Interventional's $22M Series C to advance its transcatheter tricuspid valve technology.
Medical device company based in Plymouth, MN developing an investigational percutaneous transcatheter tricuspid valve replacement (TTVR) system intended to treat tricuspid regurgitation
Medical device company based in Plymouth, MN developing an investigational percutaneous transcatheter tricuspid valve replacement (TTVR) system intended to treat tricuspid regurgitation. The company has progressed through preclinical work to first-in-human procedures and a US Early Feasibility Study, and has advanced both trans-jugular and trans-femoral delivery approaches.